Bayer announces positive results from phase III REVEAL study of investigational PET/CT radiotracer 124 evuzamitide: Berlin, Germany Friday, May 8, 2026, 16:00 Hrs [IST] Bayer anno ...

Company to Host Conference Call Today, May 7th, at 4:30pm ETBOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term ...

I 124 evuzamitide is an investigational PET radiotracer–a radioactive diagnostic imaging agent injected into the body before ...

Keratoconus is a progressive eye disease that weakens and thins the cornea, the clear front surface of the eye. In its early, ...

Innovative ASX healthcare companies are working to reduce costly and ongoing challenge of post-surgery complications. ...

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \"Telix\") today announces that the marketing authorization application (MAA) ...

Keratoconus is a progressive eye disease that weakens and thins the cornea, the clear front surface of the eye. In its early, subclinical stage, the cornea can still appear normal on routine exams.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.

Optiscan and EMVision are among ASX healthcare companies reporting clinical milestones reached in quarterly results.

Researchers preparing to scan a human heart from a donor. (ESRF/Stef Candé) A pioneering project has revealed the human body ...